Greg Hoffman

Greg Hoffman

Company: Arbor Biotechnology

Job title: Vice President Platform & Discovery


Tailoring Gene Editing Therapies from Discovery through Preclinical Development Using Analytical Methods For Benchmarking Small CRISPR Cas Nucleases 4:15 pm

Arbor is developing genetic medicines using a wholly owned portfolio of proprietary gene editing enzymes, including CRISPR cas nucleases with small sizes and unique properties that enable breakthrough applications. Arbor nucleases are mined from metagenomes, engineered using a high-throughput pipeline, and optimized for activity in therapeutically relevant cellular contexts. We will discuss analytical approaches for…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.